| 摘要: |
| 目的:探讨艾地苯醌对帕金森患者非运动状态及miR-486-5p、miR-221的影响。方法：选取2020年1月至2021年5月于本院收治的94例帕金森患者,依据随机数表法将患者分为观察组及对照组,对照组(n=47)给予美多芭口服治疗,观察组(n=47)在对照组的基础上给予艾地苯醌口服治疗,治疗12周后比较两组患者临床疗效、非运动状态[非运动症状评价量表(NMSS)]、步态状态、认知情况[简明智能量表(MMSE)与蒙特利尔认知量表(MoCA)]、炎症因子[血清核转录因子-p65、肿瘤坏死因子-α(TNF-α)及白细胞介素-6(IL-6)]、脑神经递质[去甲肾上腺素(NE)、多巴胺(DA)及5-羟色胺(5-HT)]、miR-486-5p、miR-221表达等。结果：观察组患者临床总有效率高于对照组(70.21% vs 42.55%)(χ2=7.311,P=0.007)；与对照组治疗后比较,观察组患者非运动状态严重程度与发生频率评分更低(P＜0.05)；观察组患者治疗后步长增加长度长与对照组(P＜0.05),观察组患者治疗后步速及步频低于对照组(P＜0.05)；观察组患者治疗后MMSE及MoCA评分高于对照组(P＜0.05)；观察组患者治疗后核转录因子-p65、TNF-α及IL-6水平低于对照组(P＜0.05)；观察组患者NE、DA及5-HT水平高于对照组(P＜0.05)；治疗后,观察组患者miR-486-5p水平高于对照组,miR-221水平高于对照组(P＜0.05)。结论：对于帕金森患者选择艾地苯醌治疗能下调miR-486-5p水平表达,促进miR-221表达,改善炎症因子与脑神经递质水平,从而改善患者的非运动症状、步态与认知情况,具有较高的应用价值。 |
| 关键词: 艾地苯醌 帕金森 非运动状态 miR-486-5p miR-221 |
| DOI： |
| 分类号: |
| 基金项目:1：国家自然科学基金资助项目(编号：81701271) |
|
| Effects of idbenone on non-motor status and miR-486-5p and miR-221 in patients with Parkinson"s disease |
|
Wang Yue
|
|
Zhengzhou Central Hospital,Zhengzhou
|
| Abstract: |
| Objective:To investigate the effect of idbenone on non-motor status, miR-486-5p and miR-221 in patients with Parkinson"s disease.Methods:A total of 94 patients with Parkinson"s disease admitted to our hospital from January 2020 to May 2021 were selected and divided into observation group (n=47) and control group (n=47) according to the random number table method. The control group (n=47) was given oral metoba treatment, and the observation group (n=47) was given oral edbenone treatment on the basis of the control group. 12 weeks after treatment compared two groups of patients" clinical curative effect, the motion state [the motor symptoms rating scale (NMSS)], gait state, cognitive situation [concise intelligence scale (MMSE) and Montreal cognitive scale (MoCA)], [nuclear transcription factor serum inflammatory markers - p65, tumor necrosis factor alpha (TNF alpha) and interleukin 6 ( IL-6)], brain neurotransmitters [norepinephrine (NE), dopamine (DA) and 5-hydroxytrypsin (5-HT)], miR-486-5p, miR-221, etc.Results:The total effective rate of the observation group was higher than that of the control group (70.21% vs 42.55%) (χ2=7.311, P=0.007). Compared with the control group after treatment, the scores of severity and frequency of non-exercise state in the observation group were lower (P < 0.05). After treatment, the step length of the observation group increased and the length of the control group was longer (P < 0.05), and the step speed and step frequency of the observation group were lower than those of the control group (P < 0.05). After treatment, the MMSE and MoCA scores of the observation group were higher than those of the control group (P < 0.05). The levels of nuclear transcription factor-p65, TNF-α and IL-6 in the observation group were lower than those in the control group after treatment (P < 0.05). The levels of NE, DA and 5-HT in the observation group were higher than those in the control group (P < 0.05). After treatment, the level of miR-486-5p and miR-221 in the observation group were higher than those in the control group (P < 0.05).Conclusion:For patients with Parkinson"s disease, the treatment with idbenone can down-regulate the expression of miR-486-5p, promote the expression of miR-221, improve the levels of inflammatory factors and brain neurotransmitters, so as to improve the non-motor symptoms, gait and cognition of patients, which has high application value. |
| Key words: Edbenone Parkinson"s disease. A state of non-motion MiR - 486-5 p miR-221 |
